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Available online 13 January 2016Objective: This study aimed to determine the impact of a ketogenic diet (KD) on neurobehavioral development
when used to treat childrenwith intractable epilepsy, conﬁrming the efﬁcacy of the KD, aswell as the correlation
between early electroencephalography (EEG) changes in the early stage with treatment efﬁcacy.
Methods:We enrolled 42 children who were starting treatment for intractable epilepsy with the classic KD pro-
tocol. The total development quotient as well as the development quotients for adaptability, gross motor move-
ments, ﬁne motor movements, language, and individual–social interaction on the Gesell developmental scales
were assessed before and after 3, 6, 12, and 18 months of KD treatment. The efﬁcacy assessment was based on
changes in seizure frequency after KD as recorded by the parents. We conducted 24-h video-EEG before and
after 1 month of KD treatment.
Results: Developmental quotients of ﬁve energy regions in the Gesell developmental scales assessment were
used to compare adaptability (P1= 0.000), gross motor movements (P2= 0.010), and ﬁne motor movements
(P3 = 0.000); the results showed signiﬁcant differences. After KD treatment at different time points, 69.0%,
54.8%, 40.5%, and 33.3% patients, respectively, achieved a ≥50% reduction in seizure frequency. The reduction
of epileptiform discharges in the awake state after 1 month of KD treatment correlated with the efﬁcacy
after 3 months of KD treatment.
Conclusions: Ketogenic diet treatment tends to be associated with improved neurobehavioral development, and
more signiﬁcant improvement can be obtainedwith prolonged treatment. The KD is safe and effective in treating
children with intractable epilepsy. Early EEG changes correlate with clinical efﬁcacy, to a certain degree.






Intractable/refractory epilepsy refers to seizures that remain
uncontrolled despite treatmentwith two ormore ﬁrst-line antiepileptic
drugs (AEDs), administered serially as monotherapies or in combina-
tion, with the dose reaching the maximum tolerated dose for an
appropriate treatment course [1]. Despite the advances in vagus nerve
stimulation and other operations and the development and clinical
use of new AEDs, 20%–30% of children eventually develop intractable
epilepsy [2].
A ketogenic diet (KD) is a high-fat, adequate-protein, and low-
carbohydrate diet administered under medical supervision, which
tends to maintain chronic ketosis in the body as well as provide
adequate protein and calories for growth and development [3]. The
KDhas becomean important treatment for childrenwith intractable ep-
ilepsy, and its effectiveness has been demonstrated in numerous studiesou 450052, PR China.
. This is an open access article under[4–8]. A broad scope of cognitive deﬁcits andbehavioral abnormalities is
associated with intractable epilepsy. However, few studies have
investigated the effects of add-on therapy with KD on the neurobehav-
ioral development. This study aimed to determine the impact of keto-
genic diet (KD) on neurobehavioral development in treating children
with intractable epilepsy, conﬁrming the efﬁcacy of KD, as well as the
correlation between early electroencephalography (EEG) changes in
the early stage with treatment efﬁcacy.
2. Patients and methods
2.1. Sample
This study involved a total of 42 children with intractable epilepsy
who visited the Rehabilitation Center of Cerebral Palsy Children in the
Third Afﬁliated Hospital of Zhengzhou University between May 2012
and June 2013 and were treated with a KD (ketogenic products
provided by Guangzhou Ketone Co. Ltd.). The inclusion criteria were as
follows: (1) patients who were ineligible for surgical treatment andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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were aged ≥6 months and ≤6 years; (3) patients whose average seizure
frequency was N4 times per month; (4) patients without a history of
treatment with a KD within the past 3 months; (5) children who were
treated with a KD for at least 3 months; and (6) children whose family
consented to treatment with a KD and provided written informed con-
sent. The exclusion criteriawere as follows: (1) thosewhowere in the ac-
tive stages of fever or infective diseases; (2) those with severe vomiting
or severe digestive, cardiovascular, respiratory, hepatic, urinary, or meta-
bolic diseases; and (3) thosewho could not receive the KD or had contra-
indications to treatmentwith aKD. This studywas approved by the ethics




After admission, all children underwent routine blood evalua-
tions, liver-, kidney-, and heart-function tests, blood lipid level
determination, urinary system color ultrasonography, 24-h video-
electroencephalography (VEEG), electrocardiography, Gesell develop-
mental scales assessments, and other related examinations. The types
and doses of the original AEDs taken within 3 months before the KD
treatment were maintained. All children eligible to receive KD treat-
ment required hospitalization. Classic KD treatment protocols were
used, that is, fasting in the beginning and a 4:1 ratio of fat to combined
proteins and carbohydrates. After admission, the KD management
group (consisting of physicians, nutritionists, and nurses) educated
the children's families (on topics such as the use of a blood ketone
meter, blood glucose meter, and electronic balance, the recording of
seizure manifestations and frequency, and treatment precautions).
Every day, the nurses supervised the families to continue the oral
administration of the correct dose of the original AEDs on schedule,
and the nutritionists supervised the diet of the children. Children
were fasted for 24 h to 48 h, during which blood ketone and blood glu-
cose levels were detected once every 6 h. Patients with blood glucose
levels lower than 2.1 mmol/L were given orange juice and underwent
continuous blood glucose level monitoring. Fasting was stopped when
the blood ketone level reached 3 mmol/L, or the fasting had lasted for
48 h. After the beginning of KD treatment, blood ketone and blood glu-
cose levels were detected once every 8 h, and the caloric requirement
was calculated according to height, weight, and other standards in
each child by the nutritionists. The planned total amount of calories in
the KD was 80% of the amount required for healthy children of the
same age, evenly divided into 3 daily portions. Children were given 1/
3 of the total amount on the ﬁrst day of KD treatment, 2/3 on the second
day, and the total amount on the third day. If adverse reactions occurred
or other special individual conditions were present during the adding-
on process, the add-on speed was adjusted. The hospital observation
period ranged from 7 to 10 days, during which adverse reactions, sei-
zure frequency, seizure severity, duration, etc. were recorded in detail.
DuringKD treatment, childrenwere given supplements of the appropri-
ate amounts of potassium citrate and various types of vitamins and
minerals according to their speciﬁc circumstances.
2.2.2. VEEG
We performed 24-h VEEG in an environment of quiet, soft lighting,
and suitable temperature, including awake, drowsy, and sleeping states.
Electrodes were placed according to the International 10–20 system, in
which the electrode in the earlobewas considered as the reference elec-
trode, with 19 leads. A bipolar lead was applied as the record electrode.
When the recording was started, the children who could cooperate
under physician supervision with hyperventilation by blowing paper,
ﬂash stimulation of 1–20 Hz, and regular tracings with open and closed
eyes. For those children who were unable to cooperate backgroundrhythms were obtained by the physician covering the patients’ eyes
when necessary.
2.2.3. Follow-up
After discharge, data on the children's seizures and diet (seizure
time,manifestation, frequency, duration, KD conditions, and adverse re-
actions) were recorded by their families. The urine ketone level was de-
tected daily, and blood ketone and blood glucose levels were detected
once a week. The nutritionists performed a weekly telephone follow-
up of the parameters speciﬁed above and adjusted the diet. Children
were required to attend outpatient visits and undergo repeat tests for
liver and kidney functions, blood glucose levels, and urinary system
color ultrasonography at 1, 2, 3, 6, 12, and 18 months of KD treatment.
They underwent 24-h VEEG before the treatment and after 1 month of
the treatment. The Gesell developmental scales scores were repeated
after 3, 6, 12, and 18 months of KD treatment. The results of the 24-h
VEEG and Gesell developmental scales assessments before and after
the treatment were analyzed by physicians with 10 and 13 years of
experience in electroencephalographic and Gesell developmental scales
assessments, respectively.
2.3. Efﬁcacy assessment
Assessment of neurobehavioral development was also performed.
The total development quotient as well as the development quotients
for adaptability, gross motor movements, ﬁne motor movements, lan-
guage, and individual–social interaction on the Gesell developmental
scales were determined before and after 3, 6, 12, and 18 months of KD
treatment. Improvements were observed in each quotient after KD
treatment. The total development quotient (DQ) was divided into 6
grades: normal (DQ N 85), boundary situation (76 ≤ DQ ≤ 85), mild
growth retardation (55 ≤ DQ ≤ 75), moderate growth retardation
(40 ≤DQ ≤ 54), severe growth retardation (25 ≤DQ ≤ 39), and extremely
severe growth retardation (DQ b 25). An improvement of ≥1 grade in
the total development quotient was considered to indicate improve-
ment in neurobehavioral development.
Reduction in clinical seizure frequencywas assessed by determining
the Engel grade [9] at 3, 6, 12, and 18 months of KD treatment: grade I
(no seizures): complete control of seizures; grade II (signiﬁcant effect):
≥75% reduction in seizure frequency; grade III (effectiveness): ≥50%
reduction in seizure frequency; and grade IV (ineffectiveness): b50% re-
duction in seizure frequency. The total efﬁciency was deﬁned as the
number of patients with favorable results (no seizures + signiﬁcant
effectiveness + effectiveness) divided by the total number of patients
and multiplied by 100%.
We also analyzed the correlation of changes in the epileptiform
discharges index corresponding to the awake and sleeping states on
24-h VEEG before and after 1 month of KD with clinical efﬁcacy after
3 months of KD treatment. The epileptiform discharge indexes at 1 h
after the children woke up and 1 h after they went to sleep were
calculated (the total time of epileptiform wave discharge(s) / total
observation time × 100%). The onset of sleep was deﬁned as the
disappearance of occipital brain waves or falling asleep and closing the
eyes. Epileptiform discharges within 30 min of each clinical seizure
were excluded to avoid changes due to the seizure. The EEG was per-
formed before and after KD treatment, at the same time of day as
much as possible to reduce the effects of circadian rhythms and AED
concentrations on epileptiform activity. Effective KD treatment was de-
ﬁned as a ≥50% reduction in clinical seizure frequency after 3, 6, 12, or
18 months of KD treatment; a reduction of b50% indicated ineffective
treatment.
2.4. Statistical analysis
Statistical analyses were performed using SPSS 17.0 software. Count
data were expressed as the number of cases (%), andmeasurement data
Table 1
Comparison of each development quotient before KD treatment and after 3, 6, 12, and 18 months of KD treatment (χ± s, score).




3 months of KD
treatment
6 months of KD
treatment
12 months of KD
treatment






Adaptability 19.79 ± 15.36 21.48 ± 15.46 22.19 ± 8.70 30.56 ± 11.99a 40.67 ± 9.71a,b 8.276 0.000
Gross motor 29.19 ± 16.27 30.21 ± 16.02 30.2 ± 12.45 33.28 ± 8.88 44.33 ± 10.72a,b 3.485 0.010
Fine motor 25.98 ± 18.51 27.83 ± 18.51 29.9 ± 14.48 40.50 ± 14.89a 52.67 ± 13.27a,b 8.781 0.000
Language 23.19 ± 15.07 24.76 ± 15.31 26.0 ± 11.94 28.83 ± 10.85 31.80 ± 10.52 1.375 0.246
Individual–social interaction 23.24 ± 14.44 25.45 ± 14.58 28.0 ± 12.81 29.94 ± 12.43 33.73 ± 12.40 2.042 0.092
KD, ketogenic diet.
a P b 0.05, compared with 6 months of KD treatment.
b P b 0.05, compared with 12 months of KD treatment.
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interquartile range. The normality of the measurement data was tested
using theKolmogorov–Smirnov test. Changes in neurobehavioral devel-
opment in each energy region before and after KD treatment were
assessed using analysis of variance. Pairwise comparisons were
performed using the least signiﬁcant difference-t method, while
heterogeneity of variance was analyzed using the Tamhane's method.
The epileptiform discharge index before KD treatment was compared
with that after 1 month of KD treatment by using the Mann–Whitney
U test, and the correlation of changes in epileptiform discharge indexes
with KD efﬁcacy was determined using the Spearman rank correlation.
P b0.05 was considered statistically signiﬁcant.
3. Results
3.1. General information
Among the 42 enrolled children, there were 26 boys and 16 girls,
aged 7 to 68 months, with a median age of 25.2 months. The course
of the disease before the treatment ranged from 2 to 51 months,
with a median of 14.4 months. The AEDs used during KD treatment in-
cluded sodium valproate oral liquid/tablets (32 patients), clonazepam
tablets (21 patients), lamotrigine tablets (16 patients), levetiracetam
(27 patients), topiramate (19 patients), and prednisone acetate tablets
(6 patients). The seizure types included 6 cases of tonic–clonic seizures,
5 cases of atonic seizures, 2 cases of typical absence seizures, 6 cases of
partial seizures, 20 cases of West syndrome, and 3 cases of Lennox–
Gastaut syndrome. All children underwent brain magnetic resonance
imaging or computed tomography. The brain imaging ﬁndings were
normal in 15 patients, while abnormalitieswere detected in 27 patients,
including pachygyria (1 patient), gray matter heterotopia (4 patients),
cerebral hypoplasia (9 patients), intracranial cyst (5 patients), and
cortical and subcortical softening focus (8 patients). The Gesell develop-
mental scales assessments revealed that 41 patients had psychomotor
retardation, including 24 with extremely severe retardation, 12 with
severe retardation, and 5 with moderate retardation. There were
4 patients with cerebral palsy and 1 patient with tuberous sclerosis.
3.2. Neurobehavioral development
Among the 42 children receivingKD treatment, 14 children achieved
≥1 grade improvement in the total development quotient on the GesellTable 2
Clinical control of seizures and retention rate in children with intractable epilepsy receiving KD
3 months of KD treatment 6 months of KD treatment
Number of cases Retention rate (%) Number of cases Retention rate (%
Grade I 9 21.4 11 26.2
Grade II 5 11.9 8 19.1
Grade III 15 35.7 4 9.5
Grade IV 13 31.0 3 7.1
Sum 42 100.0 26 61.9developmental scale. The development quotients of the 5 energy re-
gions on the Gesell developmental scales after KD treatment for 3, 6,
12, and 18 months are shown in Table 1.
3.3. Clinical efﬁcacy
A ≥50% reduction in seizure frequency was observed in 69.0%
(29/42), 54.8% (23/42), 40.5% (17/42), and 33.3% (14/42) patients
after 3, 6, 12, and 18 months of KD treatment, respectively. The seizure
control and retention rates in the children with epilepsy receiving KD
treatment for different durations are listed in Table 3. After receiving
KD treatment for 3–6 months, 7 patients quit because of unsatisfactory
efﬁcacy, 6 patients stopped the treatment because of antifeeding (diet
nonadherence) (in 2 of these, the treatment was effective), 2 patients
stopped treatment because of poor compliance of their parents, and 1 pa-
tient died. After receiving KD treatment for 6–12 months, 4 patients
stopped treatment because of poor efﬁcacy, 2 stopped treatment because
of other diseases, and 1 because of antifeeding. After receiving KD treat-
ment for 12–18months, 1 and 2 patients stopped the treatment because
of recurrent seizures and poor efﬁcacy, respectively (Fig. 1). Themain ad-
verse reactions during KD treatment were gastrointestinal symptoms,
such as vomiting, diarrhea, and constipation. Most of thesewere relieved
after symptomatic treatment. Long-term adverse reactions were one
case of kidney stones. One patient died during KD treatment. The imme-
diate cause of death was speculated to be airway obstruction due to spu-
tum, leading to suffocation, andwas not directly related to KD treatment.
3.4. Correlation of EEG changes in the early stage with clinical efﬁcacy
The epileptiform discharge indexes in the awake and sleeping states
before and after 1 month of KD treatment did not show statistically
signiﬁcant differences (Table 2). The reduction in the epileptiform
discharge index in the awake state after 1 month of KD treatment was
correlated with the efﬁcacy after 3 months of KD treatment (P =
0.029, r = 0.337), while the reduction in the epileptiform discharge
index in the sleeping state after 1 month of KD treatment was not
correlatedwith the efﬁcacy after 3months of KD treatment (P=0.119).
4. Discussion
Epilepsy is one of the most common problems among patients with
cerebral palsy, autism, mental retardation, and other forms oftreatment for different durations (n = 42).
12 months of KD treatment 18 months of KD treatment
) Number of cases Retention rate (%) Number of cases Retention rate (%)
11 26.2 10 23.8
3 7.1 2 4.8
3 7.1 2 4.8
1 2.4 1 2.4
18 42.8 15 35.8
Table 3
Epileptiform discharge indexes in the awake and sleeping states before KD treatment and after 1 month of KD treatment.
Before KD treatment 1 month of KD treatment P value
Median Interquartile Median Interquartile
Epileptiform discharge index in the awake state (%) 57.4 49.94 50.69 47.90 0.31
Epileptiform discharge index in the sleeping state (%) 60.23 35.58 51.82 37.69 0.33
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worsens the quality of life of patients. At the same time, epileptic sei-
zures often cause various neuropsychological problems for children,
such as movement retardation, decline in social adaptiveness, anxiety,
and sleep disorder. To our knowledge, this study is the ﬁrst to use the
Gesell developmental scales administered to children to assess the neu-
robehavioral development after 18months. Because of the unknown ef-
fects of KD on neurobehavioral development, comprehensive Gesell
developmental scales assessment includes adaptability, gross motor
movements, ﬁnemotormovements, language, and individual–social in-
teraction. In this study, 42 children receiving a KD were assessed using
the Gesell developmental scale, and the neurobehavioral developmentFig. 1. Exit KD during the treawas found to be signiﬁcantly improved in 14 children. Compared with
the data before KD treatment, adaptability, gross motor movement,
and ﬁne motor movement energy regions after KD treatment for 3, 6,
12, and 18 months showed statistically signiﬁcant differences. Further-
more, pairwise comparisons revealed that the energy regions of adapt-
ability and ﬁne motor movement after KD treatment for 6 months
were signiﬁcantly different from those observed after KD treatment for
12 and 18 months. The gross motor movement energy region showed
statistically signiﬁcant differences between patients receiving 12 and
18 months of KD treatment. Among these, the adaptability region is
themost important energy region and is the antecedent of future “intel-
ligence.” The language and individual–social interaction did not showtment period ﬂow chart.
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improve over time, indicating that short-term KD treatment is unlikely
to signiﬁcantly improve neurobehavioral development, and the im-
provement in neurobehavioral development is more signiﬁcant with
clinical control of seizures and prolonged KD treatment. Some studies
have reported that neurobehavioral development could be improved
to some extent with KD treatment [10–12]. Peuscher et al. [13] found
that the neurobehavioral development of children with intractable epi-
lepsy was improved by a reduction in clinical seizure frequency after KD
treatment, mainly manifesting as improvements in social and life abili-
ties. At the same time, Lambrechts et al. [14] conducted neurobehavioral
development tests in children with intractable epilepsy before and after
KD treatment, and the results showed no indication that the KD has a
negative impact on cognition or social adaptation in the short term.
There is a tendency towards an increase in mood problems. Pulsifer
et al. [11] described the effects of the KD on development and behavior,
and found a signiﬁcant improvement in cognition and behavior. In our
follow-up, some parents reﬂected that impulsive and aggressive behav-
ior were reduced in children, self-care ability and the quality of sleep
improved, and social activities and concentrating on learning in-
creased, but we did not do further statistical analysis.
The KD also exhibits good efﬁcacy in treating glucose transporter
glut syndrome, infantile spasm, and other diseases. Sinha et al. [15]
performed a meta-analysis and found that about 37% of children with
epilepsy achieved ≥90% reduction in seizures; among these, 30%
achieved a seizure reduction of 50%–90%. Suo et al. [16] assessed 317
children with intractable epilepsy treated with KD and found that
35.0%, 26.2%, and 18.6% of the patients achieved a N50% seizure reduc-
tion after 3, 6, and 12 months of treatment. In our earlier study [17] of
20 children with intractable epilepsy treated with KD, the efﬁciency at
3, 6, and 9 months was 65%, 55%, and 55%, respectively. In this study,
among the 42 children with intractable epilepsy, the retention rate
was close to that reported in the above literature, while the clinical
efﬁciency and rate of complete seizure control were slightly higher,
whichmight be associated with the greater number of patients with in-
fantile spasm and relatively good compliance of the children's families.
Whether or not the long-term clinical efﬁcacy of KD treatment can
be predicted by observing the relationship between the early improve-
ments on EEG remains to be determined. Ebus et al. [18] found that a re-
duction in epileptiform discharge index in the sleeping state after
6 weeks of KD treatment was correlated with the clinical efﬁcacy after
6 months of KD treatment. In this study, we found that the epileptiform
discharge index in the awake state was correlated with the clinical
efﬁcacy (P = 0.029, r = 0.337), which differs from the above results.
This difference may be associated with the limited seizure types and
short EEG observation time.
5. Summary and conclusions
In summary, KD treatment tends to be associated with improved
neurobehavioral development in children with intractable epilepsy,
and the improvement ismore signiﬁcantwith prolonged treatment. Ke-
togenic diet treatment is safe and effective, without signiﬁcant adverse
reactions. An EEG improvement in the early stage is correlated withclinical efﬁcacy to a certain extent. However, because of the small sam-
ple size and short follow-up duration, the relationship between neuro-
behavioral development and quality of life and school performance
and other issues require further investigation in large,multi-center, ran-
domized control studies.
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